11Nov
09Nov
EY Announces 27 Women Founders Selected for the EY Entrepreneurial Winning Women™ North America Class of 2021
EY announces the 27 women founders selected for the EY Entrepreneurial Winning Women™ North America Class of 2021. The program, now in its 14th year, identifies ambitious women entrepreneurs who are leading thriving organizations and provides them with the access, advisors and resources needed to scale their companies to their full potential as market-leading innovators. Program engagement offers participants executive education and introductions to the vast EY global entrepreneurial ecosystem as well as the Entrepreneurial Winning Women community worldwide. Teresa...
10Aug
CytoAgents’ Phase 1 Trial Results Show “Cytokine Release Syndrome” Drug Candidate Safe
Successful Completion of Phase 1 Clinical Trial, Close of Initial Equity Round of Funding, and Addition of Dr. Stanley Marks and John Friedman to Board of Directors Positions CytoAgents for Larger Series A and Phase II Trials. Read more >>
05Jan
15 Pittsburgh tech companies to watch in 2021
CytoAgents on list of top 15 Pittsburgh tech companies to watch in 2021. Read more >>
11Dec
Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19
On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. “This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre. Read more >>
10Dec
Pittsburgh-based company behind ‘promising’ new COVID-19 treatment
On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.” The Department of Community and Economic Development will announce that Pittsburgh-based biotechnology company CytoAgents has begun its Phase 1 clinical trial for COVID-19 treatment. Read more >>
10Dec
How CytoAgents’ plans for growth run far beyond Covid crisis
GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said. Out clinical trials as well as plans for growth to include other uses for the dreuge. CytoAgents is working in Australia with its partner, Novotech, on the phase one clinical trial of GP1681...Read more >>
30Nov
Teresa Whalen talks about CytoAgents and the treatment of Cytokine Storm
Teresa Whalen is the CEO of CytoAgents, a startup focused on the development of solutions to combat persistent and potentially deadly strains of Influenza, COVID19, and other viruses. Teresa’s career spans 20 years in the healthcare industry, including health technology executive, life sciences investor, and clinical pharmacist. She has brought multiple successful life-changing healthcare products to market. Read more >>
13Nov
Tech 50 2020: Honoring Pittsburgh’s Top Technology Companies
The Pittsburgh Technology Council's annual Tech 50 Awards honored technology innovation in the Pittsburgh region with a virtual gala event on Nov. 12, 2020. List includes CytoAgents CEO Teresa Whalen, RPh was selected as a finalist for Pittsburgh Technology Council's #TECH50 “CEO of the Year.” Read more >>
29Oct